Product Candidates

Clinical Trials

Phase 1 trial of EPI-7386
ESSA is conducting a monotherapy Phase 1 open-label clinical trial evaluating EPI-7386, an investigational first-in-class N-terminal domain androgen receptor inhibitor, for the treatment of adult patients with castration-resistant prostate cancer (CRPC) resistant to standard-of-care treatments.
clinicaltrials.gov
Phase 1/2 trial of EPI-7386
ESSA is conducting a combination Phase 1/2 clinical trial evaluating EPI-7386 + enzalutamide in mCRPC patients who have not yet been treated with second-generation antiandrogen therapies.
clinicaltrials.gov

Investigator Videos

Monotherapy Study

Russell Pachynski, MD, Associate Professor of Medicine, Washington University School of Medicine in St. Louis, discusses ESSA’s Phase 1 EPI-7386 monotherapy clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.

Combination Study

Andrew Laccetti, MD, MS, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses ESSA’s Phase 1/2 EPI-7386 + enzalutamide combination clinical trial with UroToday at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2023.